The possible cross-reactivity of immunoassays with structurally-related drugs was investigated. Innofluor" Certican" (FPIA) calibrators were measured by using IMx® Sirolimus assay (MEIA) and MEIA Sirolimus calibrators were analysed by using FPIA Certican" assay. Drug concentrations were measured in 95 and 100 samples from renal transplanted patients (RTP) on sirolimus or everolimus treatment by using immunoassays and LC/ESI-MSMS. A high cross-reactivity was found both for MEIA and FPIA. High correlation degrees, confirmed by the Bland-Altman and the Eksborg tests, were found between drug concentrations measured in real samples by both immunoassays (r=0.909 and r=0.970, respectively). LC/ESI-MSMS analysis of samples containing sirolimus showed no positivity for everolimus. Similarly, samples from patients on treatment with everolimus resulted negative as far as regards sirolimus. MEIA and FPIA could be considered mutually reliable and accurate alternatives for the specific-drug immunoassay. It should be noticed that in patients switching from one drug to the other unreal overestimation of the blood levels of the current administered immunosuppressant can occur.
1\1. PIERI ET AL. fully validated LC/UV and LC/ESI-MSMS methods is represented by immunoassays, which offer the opportunity to minimize sample pre-treatment, thus reducing the time between drawing a blood sample and measuring the drug concentration, an important aspect in high-throughput analyses. Abbott IMx~sirolimus microparticle enzyme immunoassay (MEIA) and Seradyn Innofluor" Certican" fluorescence polarization immunoassay (FPIA) are commonly used for Siro and Rad quantification, respectively, and numerous papers aimed at testing their efficacy in drugs quantification with respect to LC/ESI-MSMS and LC/UV methods have been published (7) (8) (9) (10) (11) . A certain grade of overestimation of the immunoassays with respect to chromatographic techniques is reported, and, despite the possibility of using immunoassays for routine drug monitoring, some authors still suggest the use of a chromatographic-based analysis in particular conditions, such as early post-transplant period, patients with difficult clinical issues and poly therapies. Another limitation in the use of immunoassays for therapeutic drug monitoring is the lower specifity compared with the chromatographic methods: while the cross-reactivity of both MEIA and FPIA is well known with respect to Siro and Rad metabolites, respectively (7-11), little is known about possible immunoassay cross-reactivity in respect to structurally-related drugs (7, 10, (12) (13) . In the specific case of sirolimus and everolimus this represents a critical aspect: despite the similar mechanism of action, as previously reported (3), the two molecules are characterised by different pharmacokinetics and there could be the need to switch patients from one drug to the other. In such cases it is still possible to use MEIA and FPIA for an effective drug monitoring or it is necessary to use specific chromatographic-based determinations in order to discriminate between the two molecules, thus avoiding overestimations of drug blood levels? Focusing on this aspect, the present paper is aimed at studying immunoassay specificity and crossreactivity towards substrate-analogous. Analyses were performed by using sirolimus MEIA on an Abbott IMx" instrument and Seradyn Innofluor" Certican" assay on an Abbott TDx Q <; instrument to quantify whole-blood levels of drugs in renal transplanted patients (RTP); all samples were analysed by LC/ESI-MSMS, in order to exclude the presence of everolimus or sirolimus in samples containing sirolimus or everolimus respectively, confirm the values obtained by immunoassays and strengthen the hypothesised cross-reactivity of the immunoassays towards structurally-related drugs.
MATERIALS AND METHODS

Study design
Ninety-five samples were collected from 53 RTP on sirolimus treatment and one-hundred samples were collected from 28 RTP on everolimus treatment. Information on the patients enrolled is reported in Table   1 . Drugs potentially effective to cross-react with both immunoassays were not allowed, and exogenous or endogenous substances did not reach blood concentrations able to interfere. Once arrived in the laboratory, each sample was split into three aliquots and stored at 20°C until MEIA, FPIA and LC/ESI-MSMS analyses were carried out. Prior formal approval from the local ethics committee was unnecessary as no supplementary blood samples were collected. In fact, the study was carried out on residual blood samples drawn from RTP in the course of routine post-transplant follow-up.
Materials
Rapamycin and 32-Desmethoxyrapamycin (DMR, used as internal standard for the LC/ESI-MSMS method) were from Wyeth-Ayerst Research Laboratories (Princeton, NJ, USA); everolimus was from Novartis Phanna AG (Basel, Switzerland). HPLC grade-solvents were from Carlo Erba (Milan, Italy). A Luna" C I8 (150 x 2.0 mm, 5 urn, 100 A) column (Phenomenex, Torrance, USA) was used for the HPLC elution of Siro, Rad and DMR. A column oven with a temperature control module (Lab Service Analytica, Italy) was used to keep the column temperature at 50°C during chromatographic elutions. LC/ESI-MSMS analyses were carried out by using a SpectraSystem P2000 HPLC modular system equipped with an AS3000 autosampler (ThennoElectron Corporation, San Jose, CA, USA) and a LCQ™DECA ion trap mass spectrometer, equipped with an electrospray ion source (Thermo).
Immunoassay quantifications of Siro and Rad blood concentrations were measured both by MEIA on an IMx analyzer (Abbott Diagnostics Division) and by FPIA (Innofluor" Certican assay Seradyn Inc.) on TDx" analyzer (Abbott Diagnostics Division). MEIA reagents and consumables were from Abbott Diagnostics Division (Abbott Park, IL, USA). FPIA reagents and consumables were from Seradyn Inc. (Indianapolis, IN, USA).
Microparticle Enzyme Immunoassay (MEIA) method
Whole blood samples were purified according to the Abbott IMx instructions. Briefly, analyte was extracted using a mixture of 150 III whole blood EDTA sample (or controls) and 300 III of the precipitation reagent. Samples were centrifuged and the supernatant was decanted into the sample well of the IMx reaction cell for the subsequent analysis. Calibration curves were constructed using rapamycin concentrations of 0.0, 3.0, 6.0, 12.0,20.0 and 30.0 ng/ml; quality control samples at three levels of concentration (5.0, 11.0 and 22.0 ng/ml) were used for daily quality control and to verify MEIA accuracy and precision.
Abbott Diagnostic Division reported an analytical sensitivity (defined as the lowest measurable concentration of rapamycin that can be distinguished from zero)~1.5 ng/mL, calculated as the concentration at two standard deviations from the mean rate count signal of the IMx rapamycin calibrator at 0 ng/mL. Accuracy, intra-and inter-day precision (expressed as CY%) ranged between -0.9% and -4.5%, 2.7% and 6.3%, 1.3% and 1.8%, respectively (7) . Data were within FDA requirements (14) .
Fluorescence Polarization Immunoassay (FPIA) method
Whole blood samples treated with EDTA were purified and analyzed according to the manufacturer's specifications. Briefly, 600 IIIsamples aliquots were added with 700 III ofmethanol and 100 IIIofInnofluor" Certican" precipitation reagent in a centrifuge tube. Samples were capped and vigorously mixedlvortexed for at least 10 seconds. Then samples were centrifuged for 8 minutes at 13400 x g and 300 III aliquots of the supernatant were pipetted into the sample cartridges loaded into the TDx® carousel for the subsequent analysis. Calibration curves were constructed using Rad concentrations of 0.0, 2.59, 4.73,9.06,18.11 and 39.78 ng/ml; quality control samples at three levels of concentration (3.95, 11.12 and 22.05 ng/ ml) were used for daily quality control and to verify FPIA accuracy and precision.
Seradyn Innofluor reported an analytical sensitivity (defined as the lowest measurable concentration of everolimus that can be distinguished from zero) of 0.80 ng/mL, calculated as the concentration at two standard deviations from the mean rate count signal of the TDx everolimus calibrator at 0 ng/mL. Accuracy, intra-and inter-day precision (expressed as CY%) ranged between -5.8% and -11.4%, 6.9% and 10.5%, 7.7% and 10.4%, respectively. Data were within FDA requirements (14) .
LC/ESI-MSMS method
Stock and working solutions of Siro, Rad and DMR used for the preparation of blood samples employed in . the construction of calibration curves and quality control samples were prepared in methanol. Stock solutions were stored at -80 DC; working solutions were kept at -20 DC.
Blood (16) . Sirolimus and everolimus calibration standards prepared in wholeblood were analyzed by LC/ESI-MSMS, using 32-Desmethoxyrapamycin (DMR) as internal standard. The linear fit appeared to be appropriate to describe the data, with correlation coefficients between 0.9914 and 0.9966 for Siro and 0.9931 and 0.9954 for Rad. The calibration standards concentrations were back-calculated, obtaining deviations from the nominal concentration (inaccuracy) between -1.2% and 4.6%, and CY% values in the range 0.3-8.0% for Siro and inaccuracy between -1.9% and 6.2%, with CY% values in the range 0.7-9.2% in the case ofRad.
The LC/ESI-MSMS chromatograms of blank samples (whole-blood from volunteers not exposed andlor in treatment with sirolimus and everolimus, spiked with the internal standard only) did not show interfering peaks co-eluting with Siro and Rad, nevertheless, the peak areas (noise) at the retention time of Siro and Rad were measured and Limit OfDetection (LOD) and Lower Limit Of Quantification (LLOQ) were calculated according to the Food and Drug Administration Guidelines (14) . The LC/ESI-MSMS method was characterised by a LOD of 0.7 ng/mL and a LLOQ of 2.4 ng/mL for sirolimus (15) and by a LOD of 0.6 ng/mL and a LLOQ of2.9 ng/mL for everolimus.
Quality control samples and samples of freerapamycin blood spiked with the analyte at the LLOQ level were used for the determination of inaccuracy, intraand inter-day precision and for both analytes these data are within FDA requirements (14) .
Data description and statistical analysis
All calibrators in the ranges 0.0-39.78 ng/ml for everolimus and 0.0-30.0 ng/ml for sirolimus were analysed in triplicate by MEIA and FPIA, respectively and the mean values were considered. For both assays cross-reactivity was determined. In particular, everolimus calibrators were measured by MEIA and assay cross-reactivity was calculated as follows: [Rad]MEIA/[Rad],argO'* 100. Similarly, sirolimus calibrators were measured by FPIA and assay cross-reactivity was calculated as: [Siro ]FPI/ [Siro Lrgcl*100. Furthermore, for both MEIA and FPIA assays the Pearson's regression analysis was applied to verify the correlation between the target concentrations and obtained ones.
Ninety-five samples from 53 RTP receiving sirolimus were analysed simultaneously by MEIA and FPIA. Moreover, LC/ESI-MSMS analysis of samples was used to exclude the presence of everolimus. Mean concentrations±SD· obtained by MEIA and FPIA were calculated and the ANaYA test followed by Newmann-Keuls test were used to assess the statistical significance of differences between the means. Moreover, the correlation between the values obtained by MEIA assay and those obtained by FPIA assay was investigated; the Pearson's regression analysis was applied to test the correlation. To assess the agreement between sirolimus concentrations obtained by FPIA and MEIA assays the Bland-Altman test was carried out. Finally, the ratios between sirolimus concentrations obtained by MEIA and FPIA assays ([Siro]ME,/[Siro]FP,A) were compared with the corresponding mean sirolimus values «[Siro]MEIA+[Siro ]FPIJ/2) and the Eksborg method was applied (17) .
One hundred samples from 28 RTP receiving everolimus were analysed simultaneously by FPIA and MEIA. Also in this case, LC/ESI-MSMS analysis of samples was used to exclude the presence of sirolimus. Data were evaluated as previously reported for sirolimus and the same statistical evaluations were used. A p value < 0.05 was considered significant.
RESULTS
MEJA cross-reactivity
Everolimus calibrators quantified by MEIA assay showed a cross-reactivity ranging from 87.6% to 119.7% (Fig. 3, panel a) . The correlation between the target concentrations and those obtained by MEIA was: y = -1.619 + 1.192 x, r = 0.997 with a standard error of the estimate of 0.88 ng/ml (Fig. 3, panel b) .
The analysis of 95 samples from 58 RTP on sirolimus treatment with MEIA and FPIA assays gave the following mean values: 8.7 ± 4.1 ng/ml and 8.7 ± 4.0 ng/ml, respectively. No statistically significant difference between the means was found. The comparison between values obtained by FPIA assay vs. MEIA assay gave the following regression equation: [Siro]FP'A = 0.988 + 0.883 [Siro]MEIA' r = 0.909 with a standard error of the estimate of 1.66 ng/ml (Fig. 4, panel a) .
The Bland-Altman analysis highlighted a good agreement between sirolimus concentrations obtained by FPIA and MEIA assays, confirmed by the slight number of values (5.3%) exceeding the fixed range ofmean±2SD (Fig. 5, panel a) .
The Eksborg test with an accepted level for accuracy of no more than 20% showed that 33% of samples did not fall within the fixed range ( Fig. 4 , panel b).
FPJA cross-reactivity
Sirolimus calibrators quantified by FPIA assay showed a cross-reactivity ranging from 77.0% to 89.1% (Fig. 3, panel c) . The correlation between the target concentrations and those obtained by FPIA was: y = 0.217 + 0.828 x, r = 0.995 with a standard error of the estimate of 1.29 ng/ml ( Fig. 3, panel d) .
The analysis of 100 samples from 28 RTP on everolimus treatment with FPIA and MEIA assays gave the following mean values: 10.1 ± 7.6 ng/ml and 10.9 ± 9.1 ng/ml, respectively. No statistically significant difference between the means was found. The comparison between values obtained by MEIA assay vs. FPIA assay gave the following regression equation: [Rad]ME'A = -0.757 + 1.156 [Rad]FP'A' r = 0.970 with a standard error of the estimate of 2.22 ng/ml (Fig. 4, panel c) .
The Bland-Altman analysis highlighted an excellent agreement between sirolimus concentrations obtained by FPIA and MEIA assays, confirmed by the negligible number ofvalues (2.0%) exceeding the fixed range of mean±2SD ( Fig. 5,  panel b ).
The Eksborg test with an accepted level for accuracy of no more than 20% showed that 33% of samples did not fall within the fixed range ( Fig. 4,  panel d) .
LCIESJ-MSMS analysis
The LC/ESI-MSMS method was used for the simultaneous quantitative determination of sirolimus and everolimus in samples ofRTPpreviously analysed by MEIA and FPIA. All 95 samples from patients on treatment with sirolimus resulted negative as far as regards everolimus. A representative example is reported in Fig. 2 (panel b, central chromatogram) , where no peak is present at everolimus retention time (5.5 min). In addition, no statistical difference between sirolimus blood concentrations obtained by MEIA assay and LC/ESI-MSMS method was found. All 100 samples from patients on treatment with everolimus resulted negative as far as regards sirolimus. A representative example is reported in Fig. 2 (panel c, upper chromatogram) , where no peak is present at sirolimus retention time (5.4 min). 
DISCUSSION
Therapeutic drug monitoring of sirolimus and everolimus is strongly recommended , in order to minimize the effects of the wide pharmacokine tic variability of both drugs that could lead either to ineffective responses or to toxicity risks. Focusing on this aspect, the availability of immunoassay s is crucial, since they allow the measurement of drug blood concentration s by a fast, simple and accurate b)
Similarly, everolimus blood concentration s did not show significant difference by using FPIA and LCI ESI-MSMS methods.
Data obtained by using the three methods are summarized in Table II . must take into consideration method specificity. In particular, the cross-reactivity of the parent drug with respect to its metabolites in antibody reaction is a well investigated aspect (7) (8) (9) (10) (11) . Moreover, a further but poorly investigated source of bias in immunoassay determinations could derive from antibody reaction with structurally-related drugs. Sirolimus and everolimus chemical structures differ only for a 2hydroxyetil chain at position 40 of the macrolide ring ( Fig. 1 ) and this position is not significant for the antigen-antibody binding. Although partially expected, the only studies investigating this analytical aspect are those of Baldelli et al (10) and Bouzas et al (13) which studied the measurement of sirolimus whole blood concentrations by using the Innofluor" Certican" assay and the determination of everolimus by using the Abbott IMx® assay, respectively. In addition, the Certican" manufacturer's insert reports that, when tested at a concentration of 10 ng/ml, sirolimus has a 74% cross-reactivity in the Innofluor" Certican" assay. On the basis of such considerations, the present paper was devoted to investigating the possible cross-reactivity of the two most widely used immunoassay kits for measuring sirolimus and everolimus whole-blood concentrations, Abbott IMx® sirolimus and Innofluor" Certican" assays, respectively. The study was carried out for both assays on the whole calibrators range, in order to assess the percentage cross-reactivities, and on real samples from RTP on sirolimus or everolimus treatment, in order to verify the accuracy of determinations, when quantifying Siro with FPIA and Rad with MEIA; furthermore, only in the present research all samples were also analysed by LC/ESI-MSMS as reference 
Fig. 4. Correlation and linear regression (panel a) and Eksborg difference plot (panel b) obtained in real samples from renal transplanted patients between slrolimus blood concentrations determined using Abbott IMx" MEIA and Seradyn Innofluor' Certican" FPIA. Correlation and linear regression (panel c) and Eksborg difference plot (panel d) obtained in real samples from renal transplanted patients between everolimus blood concentrations determined using Seradyn
Innofiuor" Certican" FPIA and Abbott IMx~; Sirolimus MEIA. method (Fig. 2) .
Results showed a concentration-dependent crossreactivity as far as regards MEIA, while FPIA crossreactivity varied in a smaller range while increasing sirolimus calibrators concentrations (Fig. 3 , panels a and c). For both drugs a clear correlation between target and measured values was obtained ( Fig. 3,  panels b and d) . Data on the cross-reactivity of both FPIA and MEIA assays confirmed Baldelli's and Bouzas' findings with regards to the investigated range (1O, 13) and resulted higher than that reported by the manufacturer' insert. Drug concentrations measured by both immunoassays presented excellent relationships, as confirmed by the significant high correlations degrees (Fig. 4 , panels a and c, for Siro and Rad, respectively). Data were not corrected with respect to the previously obtained equation correlations derived from calibrators, as suggested by Bouzas' (13), since such correction seems to' be inadequate: data from calibrators are not influenced by matrix differences as could occur in samples from RTP which may also contain different percentages of drug metabolites, factors able to influence immunoassay quantification. The Bland-Altman statistical analysis strengthened the agreement between the two assays, in fact for both Siro and be considered in the case of unavailability of the specific-drug immunoassay. It is noteworthy to underline that, when the patients are switched from one drug to the other and until they have been completely cleared of the discontinued drug, unreal overestimation of the blood levels of the current administered immunosuppressant could be found. A further contribution of the present research is that the use of LC/ESI-MSMS is of paramount importance when these issues are present. Rad almost all values fell within the statistically established limits of mean±2SD ( Fig. 5 ). Finally, in order to reveal possible increasing deviations associated to the lower analytical values, the more appropriate Eksborg test was performed. As shown in Fig. 4 (panels b and d) , also by applying this test substantial matches for MEl A and FPIA were found. As expected, when analysed by LC/ESI-MSMS the concomitant detection of both drugs was not observed, thus confirming that the two immunoassays investigated present cross-reactivity.
In conclusion, both assays could mutually represent a reliable and accurate alternative to 
